Antibody-Drug Conjugate Linker Design for Controlled Grafting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates face challenges in controlled grafting of cytotoxic agents without modifying the antibody sequence, requiring consistent work for each antibody of interest and affecting pharmacokinetics and pharmacodynamics.
Innovation Solution
A synthetic product characterized by a linker head bound to a linker body, which can be associated with a cytotoxic drug and a protein, such as an antibody, allowing for controlled attachment of cytotoxic agents without altering the antibody sequence, using a formula that includes a halogen or nucleofuge, aryl or cycloalkyl radicals, and bifunctional ligands for diagnostic or therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a cytotoxic agent is attached to the antibody via a linker, then the therapeutic index and activity are optimized, but the structure becomes more complex and heterogeneous
Solution Approach 1:
The linker is divided into distinct functional segments: a linker head with specific reactive groups for controlled antibody modification, a linker body for stability, and a drug attachment region. This segmentation allows each part to perform its function optimally while maintaining overall control over the conjugate structure.
Solution Approach 2:
The linker head contains specifically designed reactive groups (halogen or nucleofuge) that enable selective attachment to particular amino acid residues on the antibody. This local functional differentiation ensures controlled grafting at specific sites rather than random modification throughout the antibody structure.
2Manufacturing precision
If the antibody sequence is modified to introduce natural or non-natural amino acids for controlled grafting, then controlled attachment is achieved, but consistent work must be done for each antibody of interest
Solution Approach 1:
The linker head design with universal reactive groups (halogens or nucleofuges) can attach to multiple types of amino acid residues commonly found in antibodies (cysteines, lysines, serines, threonines). This universality allows the same linker chemistry to be applied to any antibody without requiring sequence modification, making the approach broadly applicable across different antibody therapeutics.
Solution Approach 2:
The linker acts as an intermediary molecule that bridges the antibody and cytotoxic drug without requiring modification of the antibody itself. The linker head provides the interface for antibody attachment while the linker body maintains stability and the drug attachment region enables cytotoxic agent conjugation, thus mediating the connection without altering the antibody sequence.
3Productivity
If the Drug-Antibody Ratio (DAR) is increased to improve activity, then the therapeutic effect is enhanced, but the pharmacokinetics and pharmacodynamics are significantly influenced
Solution Approach 1:
The linker incorporates specific structural parameters including a defined number of repeat units (r = 0, 1, or 2) and variable chain lengths (s = 1, 2, or 3), along with specific chemical groups (X1, X2, X3) that can be tuned. These parameter variations allow optimization of the linker's physical and chemical properties to maintain stable pharmacokinetics across different DAR values, enabling activity enhancement without compromising pharmacokinetic reliability.
Data Source
AI summary
Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.